Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer)

Université René Descartes Paris 5

Other

Institut National De La Sante Et De La Recherche Medicale

Université De Nantes

Centre Hospitalier Universitaire De Nantes

Université Paris Descartes

Nantes Université

Institut Francais De Recherche Pour L'exploitation De La Mer

Inserm

Sylvia Colliec-Jouault

Corinne Sinquin

Jacqueline Ratiskol

Karim Senni

Jean Guezennec

Gaston-Jacques Godeau

Patrick Durand

Florence Fioretti

Anthony Courtois

Jacqueline Jozefonvicz

Jean Millet

Pierre Weiss

Farida Gueniche

Myriam Yousfi

Gérard Raguenes

Didier Letourneur

Anne-Marie Fischer

Dominique Heymann

Sylvie Igondjo-Tchen Changotade

Alexandrine Foucault-Bertaud

Carmen Ruiz-Velasco

Grégory Korb

Maya Brigitte Baroukh

Jean-Louis Saffar

Julie Chesneau

Sabine Matou

Dominique Helley

Claire Boisset

Bernard Pellat

Bruno Gogly

Catherine Blondin

Christophe Merceron

Jérome Guicheux

Miriam Yousfi

Gerard Raguenes

Gregory Korb

Emilie Rederstorff

Jerome Guicheux

Farida Geuniche

The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.

Anti-metastatic marine bacterial exopolysaccharide derivative and uses thereof

The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerization of said native EPSs followed by a step of sulphating the resulting depolymerized derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 &#x3bc;g (m) g/ml.

Sulfated depolymerized derivatives of exopolysaccharides (EPS) from mesophilic marine bacteria, method for preparing same, and uses thereof in tissue regeneration

The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 &#x3bc;g (m) g/ml.

Sulfated depolymerized derivatives of expolysaccharides (EPS) from mesophilic marine bacteria, method for preparing the same, and uses thereof in tissue regeneration

The present invention relates to the use of fucans with a weight-average molar mass of between 5000 and 100 000 g/mol, for the purposes of bone grafting, engineering and regeneration.

Bone substitute comprising fucans and methods of making and use thereof

The invention relates to the use of certain low-molecular weight highly sulphated polysaccharide derivatives obtained from a bacterial polysaccharide for preparing a pharmaceutical composition suitable for modulating angiogenesis, particularly for use in accelerating vascular endothelial repair with a low haemorrhage risk in the event of thrombotic injuries.

Use of low-molecular-weight highly sulfated polysaccharide derivatives for modulating angiogenesis

The invention concerns the use of a sulphated polysaccharide capable of being obtained by radical depolymerization of a raw fucan derived from Pheophyceae, said polysaccharide having a molar mass not more than 10,000 g/mol, to obtain a medicine for preventing or treating vascular thrombosis, in particular venous thrombosis, arterial thrombosis and arterial restenosis.

Low molecular weight sulphated polysaccharide to obtain a medicine with antithrombotic activity

The invention concerns the use of fucanes for obtaining medicines for modulating metalloprotease and inhibiting leukocytic elastase. Said medicines help activate collagen synthesis inhibit proliferation of gingival fibroblasts, and activate proliferation of dermal fibroblasts. They are useful in particular for treating periodontal pathologies and dermal lesions.

Use of fucane for regulating the reconstruction of connective tissue

Growing community of inventors

Nantes, France

Sylvia Colliec-Jouault